• The Discovery of Protein Phosphorylation
• 45 min
  1. Phosphorylase and the origin of reversible protein phosphorylation

  • Prof. Edmond Fischer
• 21 min
  2. Three decades of protein phosphorylation and cancer: the identification and characterization of the src gene product

  • Prof. Raymond Erikson
• Protein Kinase Cascades
• 32 min
  3. Role of the PI 3-kinase signaling pathway in cell regulation and human disease

  • Prof. Lew Cantley
• The Modulation of Protein Function by Phosphorylation
• 33 min
  4. Two is the key to 14-3-3: dimeric mechanical signaling devices

  • Prof. Carol MacKintosh
• Protein Phosphatases
• 38 min
  5. Structure and mechanisms of protein phosphatases

  • Prof. David Barford
• 45 min
  6. Protein tyrosine phosphatases

  • Prof. Jack Dixon
• 49 min
  7. The regulation of MAP kinase signalling by dual-specificity protein phosphatases

  • Prof. Steve M. Keyse
• 22 min
  8. Protein phosphatase inhibitors: a distillation of cell signaling research and water toxicology

  • Prof. Carol MacKintosh
• The Structures of Protein Kinases
• 45 min
  9. Protein kinase structure, function and regulation

  • Prof. Susan Taylor
• 42 min
  10. The structural basis for the modulation of protein function by protein phosphorylation

  • Prof. Dame Louise N. Johnson
• Biological Systems that are Regulated by Reversible Phosphorylation
• 50 min
  11. Protein phosphorylation and the control of protein synthesis

  • Prof. Christopher Proud
• 62 min
  12. The role of phosphorylation in mediating cellular responses to DNA damage: the ATM-mediated DNA damage response

  • Prof. Yosef Shiloh
• 40 min
  13. Roles of AMPK in energy homeostasis and nutrient sensing

  • Prof. Grahame Hardie
• 56 min
  14. Serine kinases and T lymphocyte biology

  • Prof. Doreen Cantrell
• 30 min
  15. The interplay between protein phosphorylation and ubiquitylation in the NF-κB pathway

  • Prof. Zhijian 'James' Chen
• 58 min
  16. SMAD phosphorylation and the TGF-beta pathway

  • Prof. Joan Massagué
• Protein Kinases and Human Disease
• 58 min
  17. Function and regulation of the PDK1 kinase

  • Prof. Dario Alessi
• 63 min
  18. LKB1 pathway and its role in cancer

  • Prof. Dario Alessi
• 51 min
  19. WNK1 pathway and its role in regulating hypertension

  • Prof. Dario Alessi
• 33 min
  20. The hyperphosphorylation of tau and Alzheimer's disease

  • Prof. Michel Goedert
• Protein Kinases as Targets for the Development of Anti-Cancer Drugs
• 68 min
  21. PI3K/AKT signaling in cancer

  • Prof. Neal Rosen
• 37 min
  22. RAS and RAF signaling in melanoma: biology and therapies

  • Prof. Richard Marais
• 38 min
  23. The mTOR kinase as a target for anti-cancer drugs

  • Prof. David Sabatini
• Archived Lectures *These may not cover the latest advances in the field
• 51 min
  24. Modular protein-protein interactions provide a general mechanism to organize dynamic cellular systems

  • Prof. Tony Pawson
• 38 min
  25. AMP-activated protein kinase: regulating cellular and whole body energy balance

  • Prof. Grahame Hardie

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Phosphoinositide 3-kinase (PI3K) signaling
3. Class Ia PI3K's mediate growth factor signaling
4. Receptor tyrosine kinase signaling pathway
5. Logic network
6. Loss-of-function mutations in tumor suppressors
7. Sporadic mutations
8. Drug targets
9. Regulation of metabolism by PI3K AKT signaling
10. NVP BEZ235
11. Targets of BEZ235 (1)
12. Targets of BEZ235 (2)
13. Generation of mice with mutant PI3K p110a
14. Lung adenocarcinoma requires mutant PI3K
15. HIF-1alpha
16. Visualizing lung tumors using FDG PET
17. mTOR inhibition does not reduce tumor volume
18. Will a PI3K inhibitor kill K-Ras driven tumors?
19. AKT inhibition does not affect tumor size or activity
20. Effects of BEZ235 in K-Ras mutant tumors
21. BEZ235 specifically kills PI3K driven tumors
22. ARRY 886
23. PI3K with MEK inhibitors eradicates K-Ras tumors
24. Blocking the PI3K and MAP Kinase pathways
25. Inhibition of S6 kinase in K-Ras tumors
26. Summary
27. References

Topics Covered

• Phosphoinositide 3-kinase (PI3K) signaling
• Class Ia PI3K's and the mediation of growth factor signaling
• The receptor tyrosine kinase signaling pathway
• Loss-of-function mutations in tumor suppressors
• Sporadic mutations
• Drug targets
• Regulation of metabolism by PI3K AKT signaling
• Targets of the drug NVP BEZ235
• Generation of mice with mutant PI3K p110a
• How lung adenocarcinoma requires mutant PI3K
• HIF-1alpha
• Visualizing lung tumors using FDG PET
• How mTOR inhibition does not reduce tumor volume
• Will a PI3K inhibitor kill K-Ras driven tumors?
• How AKT inhibition does not affect tumor size or activity
• Effects of BEZ235 in K-Ras mutant tumors
• How BEZ235 specifically kills PI3K driven tumors
• The drug ARRY 886
• How PI3K with MEK inhibitors eradicates K-Ras tumors
• Blocking the PI3K and MAP Kinase pathways
• Inhibition of S6 kinase in K-Ras tumors

Links

Series:

• Protein Phosphorylation

Categories:

• Biochemistry
• Cell Biology

Talk Citation

Publication History

• Published on November 30, 2010

Financial Disclosures

• Prof. Lew Cantley, Consultant: Novartis.